Cutler Group LP Mannkind Corp Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$2.99 - $4.35 $2,119 - $3,084	709 Added 371.2%	900 $2,000
Q2 2022 Aug 04, 2022	SELL	$2.67 - $4.77 $51,555 - $92,103	-19,309 Reduced 99.02%	191 $0
Q1 2022 Apr 14, 2022	BUY	$2.62 - $4.45 $51,090 - $86,775	19,500 New	19,500 $71,000
Q1 2018 May 11, 2018	SELL	$2.28 - $3.8 $1,823 - $3,040	-800 Closed	0 $0
Q4 2017 Jan 17, 2018	BUY	$2.28 - $6.71 $1,823 - $5,368	800	800 $1,000

243

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.